Researchers Search for BRCA1 Treatment Option for Hereditary Breast Cancer
the Cancer Therapy Advisor take:
According to the National Cancer Institute, approximately 12% of women in the United States will develop breast cancer in their lifetime.
In women who inherit a BRCA1 mutation, 55% to 65% will develop breast cancer by the age of 70. Commonwealth Health Research Board awarded a grant to Deborah Kelly, PhD, and Zhi Sheng, PhD, from Virginia Tech Carilion Research Institute to study hereditary breast cancer, which may lead to possible treatment options for those who inherit the harmful BRCA1 genes in Virginia.
Breast cancer related to BRCA1 mutations are linked to poor outcomes, and residents of Virginia have a statistically poorer outcome than the rest of the United States. Dr. Kelly said that BRCA1-related tumors lack HER2 receptors, estrogen, and progesterone, which are drug targets that are effective for other types of breast cancer.
Since no targeted treatments for patients with BRCA1-related tumors exist, the disease is more aggressive and more likely to recur. A healthy BRCA1 gene is a tumor suppressor and produces a protein that assists in repairing damaged cell DNA before mitosis, or cell division.
Researchers at Virginia Tech recently received a grant to investigate hereditary breast cancer.
The grant will fund a two-year project to study the mechanisms behind hereditary breast cancer related to the BRCA1 gene.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Increased Body Mass Index May Be Predictive of Recurrence, Progression in Bladder Cancer
- Aspirin, Non-Aspirin NSAID-Use May Improve Survival Outcomes in Ovarian Cancer
- Research Indicates Imatinib Is Effective in Pediatric Patients With Chronic Phase CML
- Ribociclib FDA-Approved For Additional Indications in HR+, HER2- Advanced Breast Cancer
- Research Advances for Mutant KRAS-Driven Lung Adenocarcinoma